Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 8/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | EPM2A | O95278 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990436 | 0.91 | AURKA (0.46) | AURKARPS6KB1ABCB1ABCG2CSNK2A1 | |
| SCHEMBL3265691 | 0.87 | MAPT (0.44) | AURKAABCG2CSNK2A1KDRABCC1 | |
| SCHEMBL6584052 | 0.84 | KDM1A (0.45) | ABCG2EGFR | |
| SCHEMBL4867963 | 0.84 | AURKA (0.48) | AURKARPS6KB1ABCG2CSNK2A1KDR | |
| SCHEMBL2986229 | 0.83 | AURKA (0.45) | AURKARPS6KB1ABCB1ABCG2CSNK2A1 | |
| SCHEMBL2974728 | 0.80 | EGFR (0.49) | AURKARPS6KB1ABCB1ABCG2CSNK2A1 | |
| SCHEMBL2991831 | 0.78 | DYRK1A (0.47) | AURKARPS6KB1ABCG2CSNK2A1KDR | |
| SCHEMBL8147977 | 0.78 | SCN9A (0.50) | CSNK2A1KDRSYKEGFRERBB2 | |
| SCHEMBL8081976 | 0.78 | CSNK2A1 (0.46) | CSNK2A1SYKEGFR | |
| SCHEMBL8093515 | 0.78 | CSNK2A1 (0.46) | CSNK2A1KDRSYKEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1263503-B1 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | WYETH CORP (US) | 2005-11-02 | — | — | EP | claimed |
| EP-1000039-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | WYETH CORP (US) | 2004-06-09 | — | — | EP | claimed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| EP-0973746-B1 | SUBSTITUTED 3-CYANO QUINOLINES | WYETH CORP (US) | 2003-09-24 | — | — | EP | claimed |
| JP-2003526686-A | — | — | 2003-09-09 | — | — | JP | claimed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | claimed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | claimed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
| US-6251912-B1 | Substituted quinazoline derivatives | AMERICAN CYANAMID COMPANY | 2001-06-26 | — | — | US | claimed |
| EP-1000039-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | American Cyanamid Company (US) | 2000-05-17 | — | — | EP | claimed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | claimed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | claimed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | claimed |
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | CD2BP2, CD47, CD74 | AURKA 3198/4885RPS6KB1 1396/4885ABCB1 3775/4885 |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | AURKA 92/4885RPS6KB1 902/4885ABCB1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.